Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.15, $0.05 better than the analyst estimate of $0.10. Revenue for the quarter came in at $94 million versus the consensus estimate of $90.94 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.